Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9834873 | 0.85 | KMT2A (0.64) | ALDH1A1KMT2AKDM4EHTR2CMAPT | |
| SCHEMBL9344657 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL6989315 | 0.74 | PDK1 (0.51) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL6996021 | 0.73 | MEN1 (0.43) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL23460078 | 0.73 | KDM4E (0.50) | ALDH1A1KMT2AKDM4EHTR2CMEN1 | |
| SCHEMBL8792481 | 0.73 | KDM4E (0.38) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL15774873 | 0.72 | KMT2A (0.64) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL1425950 | 0.72 | HTR2C (0.38) | ALDH1A1KMT2AKDM4EHTR2CMEN1 | |
| SCHEMBL871448 | 0.70 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL4791960 | 0.70 | PKM (0.39) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855486-B1 | SPIRO TETRAHYDRO-BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARES TRADING SA (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
| EP-2855486-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | Ares Trading SA (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013178322-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2013-12-05 | — | — | WO | disclosed |
| EP-0927177-B1 | NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6274619-B1 | FUSED AMIDINO TYPE COMPOUNDS SUCH AS 4-(N-BUTYLCARBAMOYLMETHYLIDENE)-2-AMIDINO-4,5,6,7-TETRAHYDROBE NZO(B)THIOPHENE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-14 | — | — | US | disclosed |
| US-6093710-A | AN ENZYME INHIBITOR TREATING ANGIOGENESIS, ARTHRITIS, INFLAMMATION, METASTASIS, OSTEOPOROSIS, TUMORSANGIOGENESIS-DEPENDENT RETINOPATHIES, CONTRACEPTIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, BACE2 | ALDH1A1 764/4885KMT2A 3382/4885KDM4E 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.